

# **Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenström Macroglobulinemia**

**Friday, December 6, 2019**

**6:30 PM – 9:00 PM**

**Orlando, Florida**

**Moderator**

**Neil Love, MD**

**Faculty**

**Jesús G Berdeja, MD**

**Sagar Lonial, MD**

**María-Victoria Mateos, MD, PhD**

**Nikhil C Munshi, MD**

**Robert Z Orlowski, MD, PhD**

**Noopur Raje, MD**

**Research  
To Practice®**

# Disclosures for Moderator Neil Love, MD

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

# Agenda

**Module 1 – Dr Raje:** *Up-Front Management of Multiple Myeloma (MM)*

**Module 2 – Dr Munshi:** *Consolidation and Maintenance Therapy; Emerging Role of Minimal Residual Disease (MRD)*

**Module 3 – Dr Mateos:** *Current Management of Relapsed/Refractory (R/R) MM*

**Module 4 – Dr Lonial:** *Novel Strategies Under Investigation for the Treatment of MM*

**Module 5 – Dr Berdeja:** *Therapeutic Strategies Targeting B-Cell Maturation Antigen (BCMA) in MM*

**Module 6 – Dr Orlowski:** *Amyloidosis (AL) and Waldenström Macroglobulinemia (WM)*

# ASH Working Group Participants



**Warren S Brenner, MD**  
Boca Raton, Florida



**Gautam Kale, MD, MS**  
Greensboro, North Carolina



**Khuda Dad Khan, MD, PhD**  
Louisville, Kentucky



**Zanetta S Lamar, MD**  
Naples, Florida



**Neil Morganstein, MD**  
Summit, New Jersey



**Namrata I Peswani, MD**  
Orland Park, Illinois